tp53诱导的糖酵解和凋亡调节因子对肝癌预后的影响:与肿瘤微环境和铁下垂有关。

IF 11.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Liver Cancer Pub Date : 2024-08-12 eCollection Date: 2025-03-01 DOI:10.1159/000540180
Katsuya Toshida, Shinji Itoh, Norifumi Iseda, Shugo Tanaka, Kensuke Nakazono, Takahiro Tomiyama, Shohei Yoshiya, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Koji Taniguchi, Yoshinao Oda, Tomoharu Yoshizumi
{"title":"tp53诱导的糖酵解和凋亡调节因子对肝癌预后的影响:与肿瘤微环境和铁下垂有关。","authors":"Katsuya Toshida, Shinji Itoh, Norifumi Iseda, Shugo Tanaka, Kensuke Nakazono, Takahiro Tomiyama, Shohei Yoshiya, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Koji Taniguchi, Yoshinao Oda, Tomoharu Yoshizumi","doi":"10.1159/000540180","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>TP53</i>-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and its biological role in hepatocellular carcinoma (HCC) are limited.</p><p><strong>Methods: </strong>A total of 386 patients with HCC who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR was performed. Additionally, the regulation of malignant activity and ferroptosis by TIGAR was investigated in vitro.</p><p><strong>Results: </strong>Patients were divided into TIGAR-positive (<i>n</i> = 80, 20.7%) and -negative (<i>n</i> = 306, 79.3%) groups. TIGAR positivity was significantly correlated with lower albumin, higher α-fetoprotein/ <i>des</i>-gamma-carboxyprothrombin, larger tumor size/number of tumors, and greater proportions of BCLC staging C/single nodular type/poor differentiation/microscopic vascular invasion/microscopic intrahepatic metastasis. In multivariate analysis, TIGAR positivity was an independent prognostic factor (<i>p</i> < 0.0001). In addition, TIGAR positivity was significantly associated with a smaller number of cluster of differentiation (CD) 8-positive T cells (<i>p</i> = 0.0450), larger number of CD68-positive macrophages (<i>p</i> = 0.0058), larger number of programmed death-ligand 1-positive cases (<i>p</i> = 0.0002), and larger number of vessels that encapsulate tumor cluster-positive cases (<i>p</i> = 0.0004). In vitro, <i>TIGAR</i> knockdown decreased cell motility and induced ferroptosis. <i>TIGAR</i> knockdown inhibited the phosphorylation of adenosine monophosphate-activated protein kinase and acetyl-CoA carboxylase. Ferroptosis induced by <i>TIGAR</i> knockdown was inhibited by liproxstatin and baicalein treatment. The combination of <i>TIGAR</i> knockdown and lenvatinib further induced ferroptosis.</p><p><strong>Conclusion: </strong>High expression of TIGAR impacted the clinical outcome of HCC patients and TIGAR was associated not only with tumor microenvironment but also with resistance to ferroptosis.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"36-57"},"PeriodicalIF":11.6000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936447/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association with Tumor Microenvironment and Ferroptosis.\",\"authors\":\"Katsuya Toshida, Shinji Itoh, Norifumi Iseda, Shugo Tanaka, Kensuke Nakazono, Takahiro Tomiyama, Shohei Yoshiya, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Koji Taniguchi, Yoshinao Oda, Tomoharu Yoshizumi\",\"doi\":\"10.1159/000540180\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong><i>TP53</i>-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and its biological role in hepatocellular carcinoma (HCC) are limited.</p><p><strong>Methods: </strong>A total of 386 patients with HCC who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR was performed. Additionally, the regulation of malignant activity and ferroptosis by TIGAR was investigated in vitro.</p><p><strong>Results: </strong>Patients were divided into TIGAR-positive (<i>n</i> = 80, 20.7%) and -negative (<i>n</i> = 306, 79.3%) groups. TIGAR positivity was significantly correlated with lower albumin, higher α-fetoprotein/ <i>des</i>-gamma-carboxyprothrombin, larger tumor size/number of tumors, and greater proportions of BCLC staging C/single nodular type/poor differentiation/microscopic vascular invasion/microscopic intrahepatic metastasis. In multivariate analysis, TIGAR positivity was an independent prognostic factor (<i>p</i> < 0.0001). In addition, TIGAR positivity was significantly associated with a smaller number of cluster of differentiation (CD) 8-positive T cells (<i>p</i> = 0.0450), larger number of CD68-positive macrophages (<i>p</i> = 0.0058), larger number of programmed death-ligand 1-positive cases (<i>p</i> = 0.0002), and larger number of vessels that encapsulate tumor cluster-positive cases (<i>p</i> = 0.0004). In vitro, <i>TIGAR</i> knockdown decreased cell motility and induced ferroptosis. <i>TIGAR</i> knockdown inhibited the phosphorylation of adenosine monophosphate-activated protein kinase and acetyl-CoA carboxylase. Ferroptosis induced by <i>TIGAR</i> knockdown was inhibited by liproxstatin and baicalein treatment. The combination of <i>TIGAR</i> knockdown and lenvatinib further induced ferroptosis.</p><p><strong>Conclusion: </strong>High expression of TIGAR impacted the clinical outcome of HCC patients and TIGAR was associated not only with tumor microenvironment but also with resistance to ferroptosis.</p>\",\"PeriodicalId\":18156,\"journal\":{\"name\":\"Liver Cancer\",\"volume\":\"14 1\",\"pages\":\"36-57\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936447/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000540180\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540180","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

tp53诱导糖酵解和凋亡调节因子(TIGAR)是p53的靶蛋白,在糖酵解和氧化还原平衡中起关键作用。关于TIGAR对预后的影响及其在肝细胞癌(HCC)中的生物学作用的报道有限。方法:共纳入386例行肝切除术的HCC患者。对TIGAR进行免疫组化染色。此外,我们还在体外研究了TIGAR对恶性肿瘤活性和铁下垂的调节作用。结果:患者分为tigar阳性组(n = 80, 20.7%)和阴性组(n = 306, 79.3%)。TIGAR阳性与较低的白蛋白、较高的α-胎蛋白/ - γ -羧凝血酶原、较大的肿瘤大小/肿瘤数量、BCLC分期C/单结节型/分化差/显微血管侵犯/显微肝内转移的比例显著相关。在多因素分析中,TIGAR阳性是一个独立的预后因素(p < 0.0001)。此外,TIGAR阳性与分化簇8阳性T细胞数量较少(p = 0.0450)、cd68阳性巨噬细胞数量较多(p = 0.0058)、程序性死亡配体1阳性病例数量较多(p = 0.0002)和包裹肿瘤簇阳性病例的血管数量较多(p = 0.0004)显著相关。在体外,TIGAR敲低可降低细胞活力并诱导铁下垂。TIGAR敲低抑制单磷酸腺苷活化蛋白激酶和乙酰辅酶a羧化酶的磷酸化。利普司他汀和黄芩素可抑制TIGAR下调所致的铁下垂。TIGAR下调和lenvatinib联合用药进一步诱导铁下垂。结论:TIGAR的高表达影响HCC患者的临床预后,TIGAR不仅与肿瘤微环境有关,还与对铁下垂的抵抗有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association with Tumor Microenvironment and Ferroptosis.

Introduction: TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and its biological role in hepatocellular carcinoma (HCC) are limited.

Methods: A total of 386 patients with HCC who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR was performed. Additionally, the regulation of malignant activity and ferroptosis by TIGAR was investigated in vitro.

Results: Patients were divided into TIGAR-positive (n = 80, 20.7%) and -negative (n = 306, 79.3%) groups. TIGAR positivity was significantly correlated with lower albumin, higher α-fetoprotein/ des-gamma-carboxyprothrombin, larger tumor size/number of tumors, and greater proportions of BCLC staging C/single nodular type/poor differentiation/microscopic vascular invasion/microscopic intrahepatic metastasis. In multivariate analysis, TIGAR positivity was an independent prognostic factor (p < 0.0001). In addition, TIGAR positivity was significantly associated with a smaller number of cluster of differentiation (CD) 8-positive T cells (p = 0.0450), larger number of CD68-positive macrophages (p = 0.0058), larger number of programmed death-ligand 1-positive cases (p = 0.0002), and larger number of vessels that encapsulate tumor cluster-positive cases (p = 0.0004). In vitro, TIGAR knockdown decreased cell motility and induced ferroptosis. TIGAR knockdown inhibited the phosphorylation of adenosine monophosphate-activated protein kinase and acetyl-CoA carboxylase. Ferroptosis induced by TIGAR knockdown was inhibited by liproxstatin and baicalein treatment. The combination of TIGAR knockdown and lenvatinib further induced ferroptosis.

Conclusion: High expression of TIGAR impacted the clinical outcome of HCC patients and TIGAR was associated not only with tumor microenvironment but also with resistance to ferroptosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Liver Cancer
Liver Cancer Medicine-Oncology
CiteScore
20.80
自引率
7.20%
发文量
53
审稿时长
16 weeks
期刊介绍: Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信